The use of oral pilocarpine in xerostomiaand sjögren's syndrome
References (24)
Sjogren's syndrome: historical overview and clinical spectrum of disease
Rheum Dis Clin North Am
(1992)- et al.
Salivary and oral components of Sjogren's syndrome
Rheum Dis Clin North Am
(1992) - et al.
Effects of pilocarpine on salivary flow in patients with Sjogren's syndrome
Oral Surg Oral Med Oral Pathol
(1991) - et al.
Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia
Int J Radiat Oncol Biol Phys
(1997) - et al.
Oral pilocarpine for radiation induced xerostomia: integrated efficacy and safety results from two prospective randomized clinical trials
Int J Radiat Oncol Biol Phys
(1995) - et al.
Pilot study of controlled-release pilocarpine in normal subjects
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
(1996) - et al.
Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients
Am J Med
(1980) Cholinergic agonists
- et al.
Effect of pilocarpine and a beta adrenergic blocking agent on human saliva
Pharmacol Ther Dent
(1971) - et al.
The effect of pharmacological agents on salivary secretion and composition in man
J Oral Ther Pharmacol
(1967)
Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction
Oral Surg Oral Med Oral Pathol
Effectiveness of pilocarpine in postradiation xerostomia
Cancer
Cited by (44)
Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations
2007, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and EndodontologyCitation Excerpt :The drug stimulates water and electrolyte flow, and perhaps also other salivary components such as mucin. Secretory stimulation by these agents requires that residual functional salivary gland tissue be present; for review see Nusair and Rubinow.151 The side effects include excessive sweating, rhinitis, and urinary and gastrointestinal (GI) disturbances.
Salivary gland gene therapy
2006, Dental Clinics of North AmericaCitation Excerpt :Pilocarpine and civemilene are muscarinic receptor agonists that are used to stimulate salivary secretions in patients with remaining parenchymal tissue. These treatments help to improve symptoms locally [68], but these are not useful for managing the immune features of SS. Develop new treatment strategies for SS is important.
Sjögren syndrome in obstetric and gynecology: Literature review
2006, Journal de Gynecologie Obstetrique et Biologie de la ReproductionMinor gland saliva flow rate and proteins in subjects with hyposalivation due to Sjögren's syndrome and radiation therapy
2005, Archives of Oral BiologyCitation Excerpt :The reduced function of the salivary glands in pSS is due to lymphatic infiltration of the organs.3 Patients with pSS are therefore expected to have some residual salivary function,4 and respond to stimulation of their major and minor salivary glands.5 In RT patients, the reduced secretion rates are due to irreversible, degenerative processes in the glands.
Sjögren syndrome. New therapeutic approaches
2005, Medicina Clinica